Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2018 14:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Offer All Public Libraries and YMCAs in the U.S. Free Opioid Awareness Education and NARCAN® (naloxone HCl) Nasal Spray

New initiatives make free doses and educational materials available to thousands of public libraries & YMCAs in the U.S. GAITHERSBURG, Md., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Emergent...
October 15, 2018 16:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan® (Naloxone HCI) Nasal Spray

GAITHERSBURG, Md., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN®...
October 11, 2018 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Release Third Quarter 2018 Financial Results and Conduct a Conference Call on November 1, 2018

GAITHERSBURG, Md., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 1, 2018 at 5:00 pm (Eastern Time) to discuss the...
October 05, 2018 03:17 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions schließt Übernahme von Spezialimpfstoffunternehmen PaxVax ab

GAITHERSBURG, Maryland (USA), Oct. 05, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) hat heute bekanntgegeben, dass es die Übernahme von PaxVax abgeschlossen hat, einem...
October 04, 2018 18:27 ET | Source: Emergent BioSolutions

Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax

GAITHERSBURG, Md., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of PaxVax, a company focused on developing,...
August 28, 2018 16:31 ET | Source: Emergent BioSolutions

Emergent BioSolutions Joins Effort to Combat National Public Health Threat From Opioid Overdose Through Acquisition of Adapt Pharma and Its Flagship Product NARCAN® (naloxone HCl) Nasal Spray

Acquisition advances Emergent’s mission, vision and strategic growth plan by: Diversifying and expanding company’s presence within the public health threats market to respond to the opioid crisis,...
August 17, 2018 07:00 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences

GAITHERSBURG, Md., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following...
August 16, 2018 06:15 ET | Source: Emergent Biosolutions, Inc.

CEPI vergibt Vertrag im Wert von bis zu 36 Mio. US-Dollar zur Entwicklung eines Impfstoffs gegen das Lassa-Virus an Profectus BioSciences und Emergent BioSolutions

OSLO, Norwegen, BALTIMORE und GAITHERSBURG, Maryland, USA, Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (die Coalition for Epidemic Preparedness Innovations) gab heute eine neue Kooperation mit Profectus...
August 16, 2018 06:15 ET | Source: Emergent BioSolutions

CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine

OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus...
August 16, 2018 06:15 ET | Source: Emergent Biosolutions, Inc.

Cepi、ラッサウイルスのワクチン開発に向けて、プロフェクタス･バイオサイエンシズおよびエマージェント･バイオソリューションズと最大3,600万ドル相当の契約を締結

オスロ, Aug. 16, 2018 (GLOBE NEWSWIRE) -- メリーランド州ボルチモアおよびゲイサーズバーグ発 (グローブニューズワイヤ) -- CEPI (Coalition for Epidemic Preparedness Innovations、「伝染病蔓延対策の革新のための連合」) は本日、プロフェクタス･バイオサイエンシズ (Profectus...